IL13 and nasal cavity polyp: A first trial with dupilumab, an anti-IL-4 receptor alpha antagonist blocking IL-4 and IL-13 activities,15 showed that a broader impact on type 2 immune reactions does lead to the reduction of IgE as well as of local mucosal eosinophil migration from the blood and activation,17 resulting in an even more pronounced effect on nasal polyps, smell, quality of life and asthma comorbidity.